Dss, Inc. · AMEX:DSS
Dss — Investor Presentation (December 2022)
13 slides from Dss's investor presentation, Dec 7, 2022
Slide 1: Unlocking Value and Delivering Shareholder Equity
Unlocking Value and Delivering Shareholder Equity 2022 INVESTOR PRESENTATION
Slide 2: Who Is DSS?
Who Is DSS? DSS is a multi-national and diverse portfolio company that now operates 9 business lines with over 40 subsidiaries. Our Ethos DSS empowers companies to create value and enable opportunistic transformation spurred by innovation, industry needs, and asset acquisitions. Our Expertise DSS st
Slide 3: Our Business Lines
Our Business Lines 9 Business ➔ Product Packaging ➔ Biotechnology Lines ~40 ➔ Direct Marketing ➔ Commercial Lending Subsidiaries ➔ Securities and Investment Management ➔ Alternative Trading ➔ Digital Transformation ➔ Secure living Multiple ➔ Alternative Energy High-Growth Sectors 3
Slide 4: Market Potential: Why Invest in These Areas?
Market Potential Product packaging is projected to surpass $1.3 trillion by Why Invest in 2028. These Areas? Biotechnology market is expected to be worth around $3.44 trillion by 2030. The markets we are working in have unlimited potential. The opportunities Direct Marketing is a global business gen
Slide 5: How Do We Create Shareholder Value?
How Do We Create Shareholder Value? Key Areas for Growth 1. Buying Assets: Securing vehicles and infrastructure to be able to generate revenue. 2. Business Optimization: Identifying the business needs and empowering those businesses to be successful. 3. Positive EBITDA: Achieving positive EBITDA by
Slide 6: How we have put the Capital to Work
How we have put the Capital to Work… American Medical REIT (AMRE) • Acquired five medical facilities, totaling approximately 360,000 sq. ft. of quality healthcare assets across the US and more than $90 million in assets. • Generates average yields of approximately eight percent, and we have a massiv
Slide 7: Planned Spinoffs for 2023
Planned Spinoffs for 2023 Impact Biomedical Inc. is an emerging APB provides an integrated suite of financial human healthcare company and is a wholly services for businesses that shall include owned subsidiary of DSS, Inc. The company commercial business lines of credit, land is evaluating strategi
Slide 8: Our Growth
Our Growth Revenues ▲172% Total Assets ▲$264 Million Asset Growth ▲200% 8 8
Slide 9: DSS, Inc. Asset Growth
DSS, Inc. Asset Growth ASSET GROWTH $300,000,000 $250,000,000 $200,000,000 $150,000,000 $100,000,000 $50,000,000 $- 2019 2020 2021 Q3 2022 Cash and Cash Equivalents Total Current Assets Investments Total Long Term Assets Total Assets 9
Slide 10: DSS, Inc. Revenue Growth
DSS, Inc. Revenue Growth $40 $35 $30 $25 Revenue Millions $20 $15 $10 $5 $- 2019 2020 2021 Q3 2022 10
Slide 11: Increasing Shareholder Value & Stock Price
Increasing Shareholder Value & Stock Price Our Projected Goals and Metrics ● Sectors are Poised for Upside ● Gaining Value and Liquidity through IPOs ● Increasing Improving Revenue ● Improving Net Income ● Improving Adjusted EBITDA 11
Slide 12: Leadership
Frank D. Heuszel Chief Executive Officer Leadership Areas of expertise: Asset Management, Financial Engineering and Legal Our leadership team consists of global Jason T. Grady business professionals with immense Chief Operating Officer, expertise and diversified talent. President of Premier Packagin
Slide 13: Delivering Shareholder Value Contact Us
WWW.DSSWORLD.COM Delivering Shareholder Value Contact Us Investor Contact: Dave Gentry, CEO RedChip Companies Inc. (407) 491-4498 Dave@redchip.com 13